Published in Int J Cancer on April 01, 2007
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19
Liver stem cells and hepatocellular carcinoma. Hepatology (2009) 2.27
The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) (2008) 2.04
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene (2009) 1.97
CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer (2008) 1.93
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60
Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 1.51
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol (2010) 1.49
Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol (2012) 1.46
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34
Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells (2009) 1.33
Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest (2008) 1.32
Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol (2008) 1.28
Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology (2008) 1.27
CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One (2011) 1.23
Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer (2009) 1.22
CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer (2010) 1.20
CD133: to be or not to be, is this the real question? Am J Transl Res (2013) 1.12
The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res (2011) 1.10
Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer (2011) 1.09
CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One (2009) 1.09
Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res (2008) 1.08
CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem (2011) 1.08
Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol (2008) 1.08
Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer (2010) 1.07
Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel) (2010) 1.06
TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death Dis (2013) 1.05
Krüppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS One (2013) 1.05
CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol (2010) 1.04
CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer (2011) 1.02
CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer (2009) 1.02
New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer (2010) 1.01
Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol Lett (2013) 1.01
CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci (2012) 1.01
Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer (2010) 1.01
Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget (2014) 1.01
Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed) (2011) 1.00
Role of microRNAs in maintaining cancer stem cells. Adv Drug Deliv Rev (2014) 0.97
CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133- cells. Lab Invest (2011) 0.97
Colon cancer stem cells: controversies and perspectives. World J Gastroenterol (2013) 0.95
Expression profiling of stem cell signaling alters with spheroid formation in CD133(high)/CD44(high) prostate cancer stem cells. Oncol Lett (2014) 0.95
Multispecies model of cell lineages and feedback control in solid tumors. J Theor Biol (2012) 0.95
Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Mol Cancer (2014) 0.94
Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One (2011) 0.93
Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol (2014) 0.93
Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma. Oncotarget (2014) 0.93
Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/m cell cycle arrest and apoptosis. PLoS One (2012) 0.93
Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade. PLoS One (2013) 0.93
Salivary gland cancer stem cells. Oral Oncol (2013) 0.92
CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS One (2013) 0.91
Stem cells, colorectal cancer and cancer stem cell markers correlations. Curr Health Sci J (2014) 0.89
CD133(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential. Clin Exp Metastasis (2010) 0.89
CD133-positive cancer stem cells from Colo205 human colon adenocarcinoma cell line show resistance to chemotherapy and display a specific metabolomic profile. Genes Cancer (2014) 0.88
Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol (2013) 0.88
The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol (2014) 0.88
Proteome of human colon cancer stem cells: a comparative analysis. World J Gastroenterol (2011) 0.88
C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget (2016) 0.87
G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma. PLoS One (2013) 0.87
Stem cell origins and animal models of hepatocellular carcinoma. Dig Dis Sci (2009) 0.87
Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res (2013) 0.87
CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study. Exp Ther Med (2012) 0.86
Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol (2013) 0.86
Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers. Liver Cancer (2013) 0.86
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res (2013) 0.86
Biological characteristics of CD133(+) cells in nasopharyngeal carcinoma. Oncol Rep (2013) 0.86
Epithelial mesenchymal transition and cancer stem cells in esophageal adenocarcinoma originating from Barrett's esophagus. Oncol Lett (2012) 0.86
Pathway and network approaches for identification of cancer signature markers from omics data. J Cancer (2015) 0.86
Research progress and prospects of markers for liver cancer stem cells. World J Gastroenterol (2015) 0.86
Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem (2014) 0.85
Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mol Cancer (2011) 0.85
Oral epithelial stem cells - implications in normal development and cancer metastasis. Exp Cell Res (2014) 0.84
Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells (2015) 0.84
Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells. PLoS One (2013) 0.84
Label-free quantitative proteomics of CD133-positive liver cancer stem cells. Proteome Sci (2012) 0.84
Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem (2012) 0.84
Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget (2015) 0.84
Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev (2013) 0.84
Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1-6 cells. Onco Targets Ther (2013) 0.83
Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme. Cell Mol Neurobiol (2008) 0.83
Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int (2014) 0.83
Characterization of CD133+ parenchymal cells in the liver: histology and culture. World J Gastroenterol (2009) 0.83
Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am (2010) 0.83
Detection of CD133 (prominin-1) in a human hepatoblastoma cell line (HuH-6 clone 5). Microsc Res Tech (2013) 0.83
Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis (2015) 0.82
Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. Am J Stem Cells (2011) 0.82
Stem cells, a two-edged sword: risks and potentials of regenerative medicine. World J Gastroenterol (2008) 0.82
8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. World J Gastroenterol (2013) 0.82
Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth. Oncotarget (2015) 0.82
Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology (2012) 0.81
Elimination of cancer stem-like "side population" cells in hepatoma cell lines by chinese herbal mixture "tien-hsien liquid". Evid Based Complement Alternat Med (2012) 0.81
Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma. BMC Cancer (2015) 0.81
Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol (2016) 0.80
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol (2010) 3.27
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood (2010) 3.03
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer (2010) 2.54
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol (2010) 2.49
Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer (2008) 2.35
Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol (2012) 2.17
The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials (2007) 2.16
Nanosecond pulsed electric fields cause melanomas to self-destruct. Biochem Biophys Res Commun (2006) 2.10
Isolation of multipotent cells from human term placenta. Stem Cells (2005) 2.03
Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J (2005) 1.96
Bifunctional magnetic silica nanoparticles for highly efficient human stem cell labeling. Nano Lett (2007) 1.91
In vivo high-resolution MR imaging of symptomatic and asymptomatic middle cerebral artery atherosclerotic stenosis. Atherosclerosis (2010) 1.90
The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging (2010) 1.88
MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology (2010) 1.88
Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer (2008) 1.88
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood (2009) 1.87
MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology (2010) 1.82
The thyroid and pregnancy: a novel risk factor for very preterm delivery. Thyroid (2005) 1.82
Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res (2005) 1.82
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol (2007) 1.70
A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence. Int J Cancer (2009) 1.64
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer (2002) 1.63
Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res (2007) 1.61
RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol (2007) 1.61
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood (2010) 1.57
Influence of maternal glucose level on ethnic differences in birth weight and pregnancy outcome. Am J Epidemiol (2002) 1.56
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood (2011) 1.55
BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Mol Cell Biol (2011) 1.52
Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int (2008) 1.47
CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood (2008) 1.47
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol (2013) 1.45
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood (2011) 1.44
A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst (2009) 1.43
A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int (2011) 1.43
Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis. Eur J Cancer Prev (2013) 1.43
Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med (2011) 1.41
Early corticospinal tract Wallerian degeneration on diffusion-weighted MR imaging after adult stroke: three cases report. Clin Neurol Neurosurg (2012) 1.40
Early experience with the modificated approach of ligation of the intersphincteric fistula tract for high transsphincteric fistula. World J Surg (2015) 1.39
Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. Liver Transpl (2005) 1.38
Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small (2008) 1.37
Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology (2011) 1.36
The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res (2005) 1.36
Vitamin D intake during pregnancy: association with maternal characteristics and infant birth weight. Early Hum Dev (2008) 1.36
Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci U S A (2004) 1.35
The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett (2003) 1.32
Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res (2006) 1.31
The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials (2009) 1.29
Apoptotic cells protect mice against lipopolysaccharide-induced shock. J Immunol (2008) 1.29
MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One (2012) 1.29
MicroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions. Nucleic Acids Res (2010) 1.29
Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology (2011) 1.27